Albert Rice

Jack Slevin

Pito Chickering

Benjamin Mayo

Benjamin Shaver

Jack Senft

Kieran Ryan

Tao Qiu

Whit Mayo

- Pediatrix Medical Group reported **Q3 2025 adjusted EBITDA of $87 million**, exceeding expectations, and provided a full-year 2025 adjusted EBITDA outlook of **$270-$290 million**.  **[0000893949_2227650_0]** 
- The company generated **$138 million in operating cash flow** in Q3 2025, ending the quarter with **$340 million in cash** and **net debt of just over $260 million**, resulting in net leverage of just under one times.  **[0000893949_2227650_1]** 
- Pediatrix repurchased **1.2 million shares** in Q3 2025, using **$21 million** in cash, and invested **$19 million** to acquire several neonatology, MFM, and OB hospitalist practices.  **[0000893949_2227650_0]** **[0000893949_2227650_1]** 
- Q3 performance was driven by **8% same-unit growth**, with pricing up **about 7.5%** due to strong RCM cash collections, increased patient acuity, contract administrative fees, and favorable payer mix.  **[0000893949_2227650_1]** **[0000893949_2227650_5]**

Pediatrix Medical Group Reports Strong Q3 2025 Results and Updates Full-Year Guidance

- **Pediatrix Medical Group** reported strong **Q3 2025 financial results**, with **revenue of approximately $493 million** and **earnings per share of $0.84**, surpassing analyst expectations.  **[893949_935621c6fc104100b42911e9862a135a]** 
- The company's **net income rose significantly to about $72 million**, and **Q3 Adjusted EBITDA increased to $87 million** from $60.2 million in the prior-year period, reflecting favorable same-unit results.  **[893949_935621c6fc104100b42911e9862a135a]** 
- Pediatrix **raised its full-year adjusted EBITDA guidance to a range of $270 million to $290 million**, indicating confidence despite ongoing healthcare industry uncertainties.  **[893949_935621c6fc104100b42911e9862a135a]** 
- The company's shares are trading at **9 times next year’s expected earnings**, up from 7 times three months earlier, and are approaching their **$17 median price target**.  **[893949_935621c6fc104100b42911e9862a135a]**

Pediatrix Medical Group Reports Strong Q3 2025 Results and Raises Full-Year EBITDA Guidance

- Pediatrix Medical Group reported **net revenue of $493 million** and **Adjusted EBITDA of $87 million** for the third quarter ended September 30, 2025.  **[893949_0001193125-25-261626_md-ex99_1.htm:0]**  Diluted earnings per share (EPS) was **$0.84**, and Adjusted EPS was **$0.67**.  **[893949_0001193125-25-261626_md-ex99_1.htm:0]** **[893949_0001193125-25-261626_md-ex99_1.htm:2]** 
- For the nine months ended September 30, 2025, the company generated **revenue of $1.42 billion** and **Adjusted EBITDA of $209.7 million**.  **[893949_0001193125-25-261626_md-ex99_1.htm:3]** 
- The company raised its full year 2025 Adjusted EBITDA outlook, now anticipating a range of **$270 million to $290 million**.  **[893949_0001193125-25-261626_md-ex99_1.htm:0]** **[893949_0001193125-25-261626_md-ex99_1.htm:3]** 
- As of September 30, 2025, Pediatrix had **cash and cash equivalents of $340.1 million** and **total debt outstanding of $602 million**.  **[893949_0001193125-25-261626_md-ex99_1.htm:3]**

Pediatrix Medical Group Reports Q3 2025 Results and Raises Full Year Adjusted EBITDA Outlook

- Pediatrix Medical Group reported **net revenue of $493 million**, **net income of $72 million**, and **Adjusted EBITDA of $87 million** for the third quarter ended September 30, 2025.  **[893949_ba62b2d858624dec8302d1295f5d17aa_0]** 
- Diluted earnings per share (EPS) for the quarter was **$0.84**, with Adjusted EPS at **$0.67**.  **[893949_ba62b2d858624dec8302d1295f5d17aa_0]** **[893949_ba62b2d858624dec8302d1295f5d17aa_2]** 
- These results were driven by **8.0 percent growth in same-unit net revenue**, attributed to strong collection activity, higher patient acuity, and a favorable payor mix.  **[893949_ba62b2d858624dec8302d1295f5d17aa_0]** 
- The company **raised its full-year 2025 Adjusted EBITDA outlook** to a range of **$270 million to $290 million**.  **[893949_ba62b2d858624dec8302d1295f5d17aa_0]** **[893949_ba62b2d858624dec8302d1295f5d17aa_2]**

Pediatrix Medical Group (MD)